The cancer drug developer has closed its initial public offering after underwriters exercised the greenshoe option.

Exscientia, a UK-based drug discovery technology developer spun out of University of Dundee, closed its initial public offering at just over $350m on Tuesday. The spinout floated in an upsized IPO last week, issuing more than 13.8 million shares priced at $22. Telecoms and internet group SoftBank’s Vision Fund 2 and Bill and Melinda Gates…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.